Spero Therapeutics to Present at Investor Conferences in March

Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that its CEO, Ankit Mahadevia, M.D., will present at two upcoming investor conferences in March 2021. The events include the Cowen 41st Annual Healthcare Conference on March 1, and the Oppenheimer 31st Annual Healthcare Conference on March 16. The presentations will focus on Spero's development of treatments for multi-drug resistant bacterial infections and rare diseases, including its lead candidate, tebipenem HBr, aimed at treating complicated urinary tract infections.

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present at the following investor conferences in March 2021:

The Cowen 41st Annual Healthcare Conference
Panel Name: Respiratory and Infections Panel
Panel Presentation Date and Time: Monday, March 1^st at 10:20 – 11:20 AM EST

Oppenheimer 31st Annual Healthcare Conference
Corporate Presentation Date and Time: Tuesday, March 16^th at 10:00 – 10:30 AM EST

Webcasts of corporate presentations may be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and Media” tab.  Replays of corporate presentations will be archived on the website for 90 days following the conclusion of each event.

About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Spero Investor and Media Contact:
Sharon Klahre
Vice President, Investor Relations
857-242-1547
IR@sperotherapeutics.com 

FAQ

What events will Spero Therapeutics CEO present in March 2021?

Spero Therapeutics CEO Ankit Mahadevia will present at the Cowen 41st Annual Healthcare Conference on March 1 and the Oppenheimer 31st Annual Healthcare Conference on March 16.

What is Spero Therapeutics' lead product candidate?

Spero Therapeutics' lead product candidate is tebipenem HBr, developed for treating complicated urinary tract infections.

Where can I access Spero Therapeutics' conference presentations?

Webcasts of the presentations can be accessed on Spero Therapeutics' website under the 'Events and Presentations' section.

What is the focus of Spero Therapeutics as a company?

Spero Therapeutics focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases.

What is the significance of the Cowen and Oppenheimer conferences for SPRO?

The Cowen and Oppenheimer conferences are significant for SPRO as they provide a platform for discussing Spero's advancements in biopharmaceuticals and attract investor interest.